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Abstract: RAF kinases are part of a conserved signaling pathway that impacts cell growth, differentiation, and survival, 
and RAF pathway dysregulation is an attractive target for therapeutic intervention. We describe two homogeneous fluo-
rescent formats that distinguish RAF pathway inhibitors from direct RAF kinase inhibitors, using B-RAF, B-RAF V599E, 
and C-RAF. A Förster-resonance energy transfer (FRET) based method was used to develop RAF and MEK cascade as-
says as well as a direct ERK kinase assay. This method uses a peptide substrate, that is terminally labeled with a FRET-
pair of fluorophores, and that is more sensitive to proteolysis relative to the phosphorylated peptide. A second time-
resolved FRET-based assay using fluorescently labeled MEK substrate was used to detect direct inhibitors of RAF kinase 
activity. The cascade assays detect compounds that interact with activated and unactivated kinases within the recapitulated 
RAF pathway, and the direct assays isolate the point of action for an inhibitor.  
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INTRODUCTION 
  Mitogen-activated protein kinase (MAPK) signaling 
pathways consist of highly conserved Ser/Thr kinases that 
form a critical link between extracellular stimuli and intra-
cellular response. MAPK signaling pathways mediate nu-
merous cellular activities, including proliferation, movement, 
differentiation, and apoptosis. There are several unique 
MAPK signaling pathways, but each propagates its signal 
via the sequential phosphorylation of a three kinase core: the 
most upstream kinase (MAPK kinase kinase, MAP3K) acti-
vates the middle kinase (MAPK kinase, MAP2K) via phos-
phorylation, which in turn phosphorylates/activates the ter-
minal kinase (MAPK). The activated MAPK can then phos-
phorylate its target substrates, which include transcription 
factors [1].  
  One of the most highly studied MAPK pathways is the 
extracellular signal-regulated kinase (ERK1/2) pathway, 
which transmits its signals through a series of activation 
steps involving receptor tyrosine kinases (RTKs), Ras, RAF 
(MAP3K), MEK (MAP2K), and ERK (MAPK). The hyper-
activation of this pathway is associated with ~30% of human 
cancers [2-4]. Numerous factors can contribute to ERK 
pathway activation, including the over-expression of RTKs 
and mutations within the RTK or Ras families [5-7]. Re-
cently, mutations in B-RAF have been identified in human 
cancers that can contribute to ERK pathway activation, and 
one specific mutation (V599E), was found to have the high-
est incidence overall and accounts for ~90% of B-RAF muta-
tions found in melanoma and thyroid cancer [8]. (Note: In 
this paper, we will use the original numbering for B-RAF; 
however, the V599E mutation is actually V600E and we 
refer the reader to the Note within [8] for a detailed descrip-
tion). 
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  Use of B-RAF V599E kinase for both in vitro and in vivo 
experimentation has revealed it to be an oncogene that 
causes a ~500-fold increase in kinase activity in vitro, prolif-
eration of cells expressing the mutant, and in vivo transfor-
mation of these cells within nude mice [8-12]. Reduction of 
mutant B-RAF levels in melanoma cells via RNA interfer-
ence decreased ERK activity and cell proliferation [13]. 
Comparison of B-RAF V599E and wild-type (WT) kinase 
domain structures suggests that the inactive WT conforma-
tion is stabilized through interactions between the glycine-
rich loop and the activation segment. V599 is found within 
this segment, and mutation to glutamate disrupts this interac-
tion and allows the mutant to assume an active conformation 
[9].  
  RAF kinases play a role in tumorigenesis, and are associ-
ated with tumor metastasis, radiation and chemo-resistance, 
and angiogenesis [14]. Tumor-induced angiogenesis is the 
process by which tumors recruit the development of new 
blood vessels from the existing endothelial vasculature. 
These new blood vessels are critical if a tumor is to grow 
more than a few millimeters in diameter [15, 16]. A key step 
in the angiogenic process initiated by tumors is the secretion 
of growth and angiogenic factors, such as vascular endothe-
lial growth factor (VEGF), basic fibroblast growth factor 
(bFGF), and platelet derived growth factor beta (PDGF-). 
These factors signal through RTKs on endothelial cells and 
ultimately through the RAF pathway. Sorafenib (Bayer, 
BAY-43-9006) is a compound that is approved for the treat-
ment of advanced renal cell carcinoma, and is the first multi-
kinase inhibitor that targets B-RAF, B-RAF V599E, and C-
RAF. Other kinases that Sorafenib inhibits play a role in 
mediating angiogenic responses (including VEGF receptor -
2 & -3, PDGF-beta receptor) and tumor growth (including 
FLT3 and c-Kit) [14, 17]. Two other compounds that inhibit 
the RAF pathway via an allosteric inhibition of MEK are 
PD-0325901 (Pfizer) and ARRY-142886 (AZD6244, Array 
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are typically referred to as either type II or type III, where 
the compound’s binding site on the kinase partially overlaps 
with the ATP binding site for type II inhibitors, or is inde-
pendent of the ATP binding site for type III inhibitors. Both 
PD-0325901 and ARRY-142886 inhibit MEK1 using an 
ATP non-competitive (type III) mode of interaction and have 
progressed into clinical trials [14, 19]. Thus, the identifica-
tion of new compounds that inhibit the RAF signaling path-
way may hold clinical benefit.  
  To address the need for simple, non-radiometric assays 
capable of identifying and characterizing inhibitors of the 
RAF signaling pathway, we have developed a series of fluo-
rescent assays suitable for high-throughput screening that 
use either Förster resonance energy transfer (FRET) or time-
resolved (TR) FRET. We will highlight the development of 
direct and cascade assays for the RAF-MEK-ERK pathway 
using C-RAF, B-RAF, and B-RAF V599E. Using reference 
compounds, we demonstrate how these assays can be used to 
biochemically interrogate the RAF pathway and identify 
ATP competitive and non-competitive inhibitors. In addition, 
we show how the FRET assays can be applied for profiling 
using greater than 230 kinases.  
MATERIALS AND METHODS 
Reagents and General Data Analysis 
  The FRET peptides were synthesized as a set containing 
a non-phosphorylated peptide substrate and phophorylated 
control peptide. The FRET peptides used for the RAF and 
MEK cascade assays as well as the ERK direct assay were 
part of the Z’-LYTE™ kinase assay kit- Ser/Thr 3 (invitro-
gen); this FRET peptide is derived from the ERK consensus 
phosphorylation site of PX(S/T)P found within myelin basic 
protein; other FRET peptides used were also from invitro-
gen. All active and unactivated kinases used in this study 
were from Invitrogen. The following kinases were all full-
length: B-RAF, unactive MEK1, active MEK1, unactive-
fluorescein-labeled MEK1, active ERK2, and unactive 
ERK2. B-RAF V599E and C-RAF consisted of the catalytic 
domains only, amino acids 416-766 for B-RAF V599E and 
306-648 for C-RAF. C-RAF also contained two point muta-
tions that rendered it constitutively active (Y340D and 
Y341D). Staurosporine was purchased from Sigma while 
GW5074, ZM336372, U0126, and PD98059 were from 
BioMol. Unless otherwise noted, all data were plotted and 
analyzed using GraphPad Prism software (GraphPad Soft-
ware, Inc., San Diego, CA). Z’ values were calculated ac-
cording to the following equation [20].  
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where c+ and c- are the standard deviations of positive and 
negative control wells, respectively, while μc+ and μc- are the 
mean values for the positive and negative control wells, re-
spectively.  
FRET-Based Kinase Assays  
  Direct FRET-based kinase assays were performed in 384-
well low-volume plates (Corning #3676) using 2 μM sub-
strate and 100 μM ATP in a 10 μL volume. The buffer con-
sisted of 50 mM HEPES pH 7.5, 10 mM MgCl2, 1  mM 
EGTA, 0.01% Brij-35. Kinase reactions were typically initi-
ated by the addition of either ATP or the active kinase and 
allowed to proceed for 1 hour at room temperature (RT). 
Following the 1 hour kinase assay, 5 μL of development 
reagent was added and the development reaction allowed to 
progress for 1 hour at RT, essentially as described previously 
[21]. The reactions were then read on a Tecan Safire™ fluo-
rescent plate reader (Tecan, Durham, NC) using an excita-
tion wavelength of 400 nm (12 nm bandpass) and emission 
wavelengths of 445 nm (12 nm bandpass) and 520 nm (12 
nm bandpass). Inhibitor titrations were performed in quadru-
plicate as follows: 2.5 μL of the inhibitor stock was added to 
a 5 μL solution of active kinase and FRET substrate, fol-
lowed by 2.5 μL of ATP to start the assay. For inhibitor pro-
filing studies using 1 μM or 10 μM BAY-43-9006, FRET-
based direct kinase assays were conducted as described 
above with the following exceptions: (1) the final ATP con-
centration was equal to the ATP Km apparent (ATP Km 
app) 
determined for each kinase in the direct FRET-based assay; 
and (2) kinase buffer composition and pH were optimized 
for each kinase.  
  FRET-based cascade assays utilizing multiple kinases in 
the pathway were conducted in a manner similar to that de-
scribed above for the direct kinase assays, with the following 
exceptions. For double (MEK-ERK) and triple (RAF-MEK-
ERK) cascade assays, it was necessary to first optimize the 
concentration of the unactivated kinase(s) prior to optimizing 
the concentration of the active kinase; this procedure is ex-
plained in the Results section. All cascade kinase reactions 
were conducted at a single ATP concentration of 100 μM. 
For the double and triple cascade assays, the amount of un-
activated ERK2 in the 10 μL kinase reaction was ~140 nM 
(or 10 μg/ml). For the three triple cascade assays, the amount 
of unactivated MEK1 in the 10 μL kinase reaction was ~ 20 
nM (or 1 μg/ml). The concentrations of active kinases in the 
double and triple cascade assays were selected to yield ~10 - 
50% phosphorylation in the absence of inhibitor, as de-
scribed in the Results (MEK1, ~4.2 nM; B-RAF, ~57 pM; B-
RAF V599E, ~10.4 pM; C-RAF, ~6.0 pM). Inhibitor titra-
tions were performed in triplicate as follows: 2.5 μL of the 
inhibitor stock was added to a 5 μL solution of (unacti-
vated/active) kinase(s) and FRET substrate, followed by 2.5 
μL of ATP to start the assay.  
  FRET-based kinase data was processed in two steps. 
First, the ratio of the coumarin:fluorescein emission intensi-
ties for each well were calculated (445 nm / 520 nm) which 
was then used to calculate the % phosphorylation using 
Equation 1. In order to apply equation 1, the 0% and 100% 
phosphorylation controls were used to establish the mini-
mum and maximum emission ratio values on each assay 
plate. The 0% phosphorylation control was obtained from a 
mock kinase reaction run in the absence of ATP. The 100% 
phosphorylation control was obtained from a mock kinase 
reaction containing fully phosphorphorylated control pep-
tide. The percent phosphorylation was calculated using the 
following equation:  
% Phosphorylation =  
( 1
(Em.Ratio F 100%)C100%
(C0% C100%)+[Em.Ratio(F 100%  F 0%)] ) x100        (1) 
in which Em. ratio is the ratio of coumarin/fluorescein emis-
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age coumarin emission signal intensity of the 100% phos-
phorylation control; C0% is the average coumarin emission 
signal intensity of the 0% phosphorylation control; F100% is 
the average fluorescein emission signal intensity of the 100% 
phosphorylation control; and F0% is the average fluorescein 
emission signal intensity of the 0% phosphorylation control. 
For the RAF, MEK, and ERK FRET-based assays, the aver-
age emission ratio ( ± standard deviation) obtained for the 
0% and 100% phosphorylation control reactions from >10 
experiments was 5.89 ± 0.15 and 0.34 ± 0.03, respectively. 
The resulting maximum signal to basal ratio determined 
from >10 experiments was >17.  
Direct TR-FRET Assay 
  Development of the TR-FRET assay for RAF using a 
fluorescein-MEK1 substrate and terbium-labeled phospho-
[Ser 217/221] MEK1 antibody has been described [22]. 
Briefly, 200 nM of fluorescein-MEK1 was used as a sub-
strate in a 10 μL assay. Reactions were conducted in the 
same 384-well plate type and kinase buffer as described for 
the FRET assays, initiated by the addition of ATP, and al-
lowed to proceed for 1 hour at RT. After one hour, a 10 μL 
solution of EDTA and terbium-labeled phospho-[Ser 
217/221] MEK1 antibody in 20 mM Tris, pH 7.5 and 0.01% 
NP-40 was added for a final well volume of 20 μL with final 
concentrations of antibody and EDTA at 2 nM and 10 mM, 
respectively. Following a 1 hour incubation at RT, plates 
were read as described previously [22]. For TR-FRET-based 
assays, the average maximum signal to basal ratio ( ± stan-
dard deviation) obtained using eight different kinases was 
8.9 ± 1.0. Inhibition assays were performed by adding 2.5 μL 
of inhibitor to a 5 μL solution of kinase and substrate, fol-
lowed by 2.5 μL of ATP. For inhibitor experiments, the final 
ATP concentration was 100 μM, while the final RAF con-
centrations were equal to the ~ EC50 in the absence of inhibi-
tor (B-RAF, 730 pM; B-RAF V599E, 49 pM; C-RAF, 220 
pM). The inhibitor studies were conducted in quadruplicate. 
RESULTS  
  Two homogeneous fluorescence-based assay formats 
were employed in our studies. The FRET-based assay uses a 
peptide substrate that is labeled at opposite ends with donor 
(coumarin) and acceptor (fluorescein) fluorophores (Fig. 
1A). The substrate is engineered to contain a proteolytic 
cleavage site proximal to the phosphorylation site, which 
results in protection of the phosphorylated peptide relative to 
the non-phosphorylated peptide from proteolysis [21]. In this 
assay, the primary kinase reaction is followed by a secondary 
development reaction, in which the kinase reaction is 
quenched and the protease reaction initiated. Non-
phosphorylated substrate is cleaved, resulting in physical 
separation of the fluorophors and a corresponding decrease 
in FRET.  
  Using this FRET-based method, cascade and direct as-
says were configured in order to recapitulate the RAF-MEK-
ERK signaling pathway in vitro and facilitate the identifica-
tion of compounds that interact at allosteric and orthosteric 
(ATP competitive) sites. The cascade assays utilize an active 
upstream kinase in combination with unactivated down-
stream kinase(s) and an appropriate FRET peptide substrate, 
which is specifically phosphorylated by the terminal down-
stream kinase ERK (Fig. 1B). In the case of the RAF path-
ways, active B-RAF, B-RAF V599E, or C-RAF was used 
with unactivated MEK1, unactivated ERK2, and an ERK-
specific peptide substrate; these assays are referred to as tri-
ple cascades due to the presence of three kinases. To allow 
further interrogation of the RAF-MEK-ERK pathway, a 
double cascade assay was developed using active MEK1 and 
unactivated ERK2. These cascade assays in combination 
with a direct ERK2 assay forms the foundation for the RAF 
pathway assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic of fluorescent assay formats used to character-
ize kinase inhibitors within the RAF-MEK-ERK pathway. (A) The 
FRET direct kinase assay uses a peptide substrate terminally la-
beled with a coumarin-fluorescein FRET pair and measures the 
amount of phosphorylated product due to a decrease in sensitivity 
of the phosphorylated peptide to proteolysis. Proteolysis of the non-
phosphorylated product decreases the FRET, while FRET is main-
tained in the phosphorylated peptide. (B) The FRET triple cascade 
kinase assay detects phosphorylation of a labeled peptide substrate, 
as described for a direct assay. However, the kinase reaction com-
ponents vary. In the case of the triple cascade assay shown, the 
kinase reaction components are active MAP3K kinase (RAF), unac-
tivated MAP2K (MEK1), unactivated MAPK (ERK2), and the 
FRET peptide substrate. (C) The TR-FRET format detects associa-
tion between a fluorescein-labeled, phosphorylated MEK1 protein 
and a terbium-labeled phospho- [Ser 217/221] MEK1 antibody. 
RAF activity is detected by an increase in the fluorescence intensity 
of the fluorescein acceptor MEK1 relative to the intensity of the 
terbium phospho-antibody donor. 
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  For efficient catalysis, many serine/threonine kinases 
require kinase/substrate interactions that can not be effec-
tively mimicked by peptide substrates, and we were unsuc-
cessful in developing a FRET peptide-based substrate that 
would be directly phosphorylated by the RAF family of 
kinases. In order to fully interrogate the RAF pathway, a 
direct TR-FRET assay was used that employs MEK1, a 
physiologic substrate for the RAF family. This assay de-
pends on the binding of a terbium-labeled phospho-[Ser 
217/221] specific antibody to a fluorescein labeled MEK1 
(Fig. 1C). Proximity-dependent FRET between the terbium-
labeled antibody and the fluorescein labeled phosphorylated-
MEK1 can be measured in a time-gated (or “time resolved”) 
manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). ERK2 Direct FRET Assay. (A) The % phosphorylation 
achieved with increasing active ERK2 in a direct assay using vari-
ous ATP concentrations. (B) Linear plot of the percent phosphory-
lation achieved for the ERK2 direct assay with 100 μM ATP, with 
R
2 >  0.99. (C) The % phosphorylation was converted to rate 
(nmole/min/mg) and plotted versus ATP concentration in order to 
determine the Vmax and ATP Km
app (14.5 nmole/min/mg and 54 μM, 
respectively). All data points are the average of duplicate determi-
nations.  
Development of Direct and Cascade FRET-Based Assays 
  Using active ERK2 in a direct FRET-based assay and 
increasing the concentration of either ERK2 or ATP, results 
in increased phosphorylation of the peptide substrate (Fig. 
2A). The percent phosphorylation for each data point was 
calculated and the concentration of ERK2 that resulted in 
~50% phosphorylation of the substrate at 100 μM ATP was 
~29 nM. Increasing the concentration of ERK2 in the assay 
results in a linear increase in the percent phosphorylation of 
the substrate achieved up to ~50% (Fig. 2B). From this data, 
an ATP Km apparent value of 54 μM was determined for 
ERK2 (Fig. 2C).  
  In order to develop the cascade assays, we took a multi-
step approach that involved the sequential optimization of 
unactivated and active kinase concentrations in the reactions. 
First, the amount of the unactivated ERK2 required for com-
plete phosphorylation of the peptide substrate in the presence 
of excess upstream kinase(s) was determined. For the double 
cascade the upstream kinase is active MEK1, while for the 
triple cascades active RAF and unactivated MEK1 are the 
upstream kinases used. In the double cascade, complete 
phosphorylation of the substrate is achieved when 200 nM 
(~10  μg/mL) active MEK1 was used with 140 nM (~10 
μg/mL) of unactivated ERK2 (Fig. 3A). For the B-RAF 
V599E triple cascade, complete phosphorylation of the sub-
strate is achieved when 150 nM (~10 μg/mL) active B-RAF 
V599E and 200 nM (~ 10 μg/mL) unactivated MEK1 were 
used with 140 nM of unactivated ERK2 (Fig. 3A). As ex-
pected, no significant phosphorylation of substrate is 
achieved under conditions lacking the full activation se-
quence for the RAF-MEK-ERK pathway: unactivated ERK2 
alone; unactivated MEK1 plus unactivated ERK2; or active 
RAF plus unactivated ERK2 (Fig. 3A). Similar results were 
obtained when B-RAF and C-RAF were used instead of B-
RAF V599E (data not shown). Therefore, a concentration of 
140 nM unactivated ERK2 was selected for subsequent ex-
periments.  
  After defining the optimal concentration of unactivated 
ERK2 to use in the assay, we then optimized the concentra-
tion of MEK1. In the case of the double cascade, active 
MEK1 was titrated with 140 nM unactivated ERK2 and 
~50% phosphorylation of the substrate was seen with ~8 nM 
active MEK1 (Fig. 3B). For the triple cascades, unactivated 
MEK1 was titrated in the presence of 140 nM unactivated 
ERK2 plus 10 μg/mL RAF. For the B-RAF V599E triple 
cascade, complete phosphorylation of the substrate was 
achieved at a concentration of unactivated MEK1 greater 
than ~6 nM (Fig. 3B). These results are similar to that ob-
served when active MEK1 is included in the assay rather 
than unactivated MEK1 (Fig. 3B). This observation suggests 
that B-RAF V599E is able to fully activate the unactivated 
MEK1 preparation, and that there is a small portion of the 
active MEK1 preparation that is unactivated but that can be 
activated by B-RAF V599E during the one hour kinase reac-
tion. As expected, no significant phosphorylation of sub-
strate is achieved under conditions lacking the full activation 
sequence for the RAF-MEK-ERK pathway (Fig. 3B). Simi-
lar results were obtained with B-RAF or C-RAF (data not 
shown). The concentration of unactivated MEK1 selected for 
subsequent use in the three triple cascade assays was 20 nM.  
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Fig. (3). (A) Determination of the amount of the unactivated down-
stream kinase (ERK2) that leads to complete phosphorylation of the 
peptide substrate in the presence of: No B-RAF V599E and 200 nM 
active MEK1 (, double cascade); 150 nM (10 μg/ml) active B-
RAF V599E and 200 nM unactivated MEK1 (, triple cascade); 
No B-RAF V599E and No MEK1 (); No B-RAF V599E and 200 
nM unactivated MEK1 (); or 150 nM (10 μg/ml) active B-RAF 
V599E and No MEK1 (). (B) Determination of the amount of 
activated MEK1 that leads to complete phosphorylation of the pep-
tide substrate in the presence of: No B-RAF V599E and 140 nM 
unactivated ERK2 (, Double cascade); ~150 nM active B-RAF 
V599E and 140 nM unactivated ERK2 (); ~150 nM active B-
RAF V599E and No ERK2 (). Determination of the amount of 
unactivated MEK1 that leads to complete phosphorylation of the 
peptide substrate in the presence of: ~150 nM active B-RAF V599E 
and 140 nM unactivated ERK2 (, triple cascade); No B-RAF 
V599E and 140 nM unactivated ERK2 (). (C) Linear plot of the 
percent phosphorylation achieved for the double cascade with in-
creasing concentration of active MEK1, using the optimized con-
centration for unactive ERK2 (140 nM), with R
2 > 0.99. All data 
points represent the mean ± standard deviation from triplicate sam-
ples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Using the optimal concentration of unactivated ERK2 of 
140 nM (~10 μg/ml) and unactivated MEK1 of 20 nM (~1 μg/ml), 
determination of amount of active B-RAF V599E to use for subse-
quent kinase inhibitor studies (, triple cascade). Control reactions 
lacking a portion of the RAF-MEK-ERK pathway were: titration of 
B-RAF V599E without MEK1 and without ERK2 (); titration of 
B-RAF V599E with 140 nM unactivated ERK2 without MEK1 
(); titration of B-RAF V599E with 20 nM unactivated MEK1 
without ERK2 (). (D) Linear plots of the percent phosphorylation 
achieved for each of the triple cascades with increasing concentra-
tions of active RAF isoform, using the optimized concentrations for 
unactive MEK1 (20 nM) and unactive ERK2 (140 nM), with R
2 > 
0.99. All data points represent the mean ± standard deviation from 
triplicate samples.  
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  The third step in the assay optimization process was to 
titrate each RAF isoform against unactivated MEK1 and 
ERK2 at the optimal concentration of each, as determined 
above (Fig. 4). For the triple cascade assays EC50 values of 
80 pM, 23 pM, and 28 pM were obtained for B-RAF, B-RAF 
V599E, and C-RAF, respectively (Fig. 4A-C). As expected, 
no significant phosphorylation of substrate was observed 
under conditions lacking the full activation sequence for the 
RAF-MEK-ERK pathway (Fig. 4A-C). Increasing the con-
centration of an active RAF in the triple cascade assays (Fig. 
4D) or active MEK1 in the double cascade assay (Fig. 3C) 
resulted in a linear increase in the percent phosphorylation of 
the substrate achieved. The Z’ value was > 0.5 at substrate 
phosphorylation levels greater than ~5 – 10% (data not 
shown). Therefore, subsequent experiments utilized concen-
trations of active RAFs or active MEK1 that resulted in 10 – 
50% phosphorylation of the peptide substrate.  
TR-FRET Direct Assay  
  Using a native substrate for RAF (i.e. MEK1), a direct 
TR-FRET assay for C-RAF has been recently reported [22]. 
In this study, RAF titrations revealed that at ATP concentra-
tions between 1 – 1000 μM, B-RAF V599E was the most 
active, followed by C-RAF, and then B-RAF; EC50 values at 
100 μM ATP were 49 pM for B-RAF V599E, 220 pM for C-
RAF, and 730 pM for B-RAF (Fig. 5A for B-RAF V599E). 
This is the same order of activity observed for the RAF iso-
forms in the FRET-based triple cascade assays. The Z’ value 
was > 0.7 when the EC30 or higher concentrations of C-RAF 
were used (data not shown). The fluorescein-MEK1 and ter-
bium-labeled phospho-[Ser217/221] MEK1 antibody assay 
also serves as a good method to quantify activity of other 
MAP3K’s beyond the RAFs (Fig. 5B).  
Inhibition of RAF-MEK-ERK Cascade and Direct Inhi-
bition of MEK 
  Cascade assays offer the potential to identify either allos-
teric or ATP competitive compounds that target unactivated 
or active kinases within the recapitulated kinase signaling 
pathway, but with this advantage comes the necessity for a 
means to identify (deconvolute) the site of action for the ac-
tive compound. Using a small set of reference inhibitory 
compounds, we used our abbreviated cascade and direct as-
says as a means to deconvolute inhibition within the RAF 
pathway. Staurosporine, a broad based ATP-competitive 
kinase inhibitor, had an IC50 of ~4 nM in the double cascade 
assay and an IC50 that is ~10-fold larger in the triple cascades 
assaying B-RAF, B-RAF V599E, or C-RAF (Table 1). A 
portion of this difference may be accounted for by the molar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Direct TR-FRET MAP3K assays. (A) The TR-FRET ra-
tios (Em 520 nm/Em 495 nm) resulting from titrations B-RAF 
V599E with one of five different ATP concentrations (1 – 1000 
μM). (B) The TR-FRET direct assay was utilized with seven dif-
ferent MAP3Ks using a final ATP concentration of 500 μM. All 
data points represent the mean ± standard deviation from triplicate 
samples. 
Table 1.  Inhibitor IC50 Values for Direct and Cascade Kinase Assays. Kinase Reactions were Conducted in the Presence of In-
creasing Inhibitor Concentrations for the FRET Direct, FRET Cascades, and TR-FRET Direct Assays Using 100 μM 
ATP 
 Inhibitor  IC50 (nM)  
Format Assay  Staur.  GW5074  ZM336372  U0126  PD98059 
FRET  Direct  ERK2  4,400  >400  >50,000 >50,000 >50,000 
FRET  Double  MEK1-ERK2  4  >400  >50,000 >10,000 >50,000 
FRET Triple  BRAF-MEK1-ERK2  56  3  400  65  420 
FRET Triple  BRAF V599E-MEK1-ERK2  69  2  32  65  300 
FRET Triple  CRAF-MEK1-ERK2  63  9  30  66  380 
TR-FRET Direct  BRAF  >50,000  15  580  >40,000  >50,000 
TR-FRET Direct  BRAF V599E  >50,000  4.9  270  >5,000 >50,000 
TR-FRET Direct  CRAF  >50,000  24  90  >50,000  >50,000 
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difference in MEK1 content, which is ~ 4 nM in the double 
cascade assay and ~20 nM in the triple cascade assay. 
Staurosporine was less effective at inhibiting the ERK2 di-
rect assay, with an ~70-fold larger IC50 than that observed 
for the triple cascades (Table 1). These results for 
staurosporine indicate that differential inhibition of kinases 
within the pathway can be detected and that IC50 values for 
potent inhibitors may be limited by the concentration of 
kinase present in the reaction. GW5074, a known RAF1 in-
hibitor, displayed complete inhibition of the three RAF triple 
cascade assays, but displayed no inhibition of either the 
ERK2 direct or MEK1-ERK2 double cascade assays (Fig. 
6A). The 9 nM IC50 determined in the triple C-RAF cascade 
(Table 1) is in close agreement with the published IC50 of 9 
nM for GW5074 of C-RAF [23]. As expected, GW5074 in-
hibited B-RAF, B-RAF V599E, and C-RAF in the direct TR-
FRET assay with rank order IC50 values in agreement with 
the triple cascade assays (Table 1), but with absolute IC50 
values 2.5 to 5- fold higher than seen in the cascade assays. 
ZM336372 has been reported to inhibit C-RAF at 10-fold 
lower IC50 relative to B-RAF [24] and the FRET-based assay 
results were consistent with this finding: ~13-fold lower IC50 
observed for the C-RAF triple cascade relative to the B-RAF 
triple cascade and no inhibition of either the ERK2 direct or 
MEK1 double cascade (Fig. 6B, Table 1). The RAF direct 
TR-FRET assays confirmed that ZM336372 acts by inhibit-
ing RAF activity and also confirmed a preference for C-RAF 
inhibition relative to B-RAF, as a ~6-fold decrease in the 
IC50 for C-RAF was found relative to B-RAF. ZM336372 
was equally potent for C-RAF and B-RAF V599E in the 
triple cascades (Fig. 6B), while ZM336372 had a ~3-fold 
lower IC50 for C-RAF relative to B-RAF V599E in the RAF 
TR-FRET direct assay.  
  U0126 is an inhibitor that has a unique mode of action in 
that it binds directly to a site that is non-competitive with 
ATP (an allosteric site) on MEK1 that prevents phosphoryla-
tion by RAF; it can bind both unactivated and active 
MEK1/2, but it is a more potent inhibitor of RAF phophory-
lation of MEK1/2 [25-27]. As expected for an inhibitor of 
RAF phophorylation of MEK1, U0126 was able to inhibit 
the three RAF triple cascades with near equal potency, ~65 
nM (Fig. 6C, Table 1). A >100-fold decrease in potency was 
observed for the MEK1 double cascade and ERK2 direct 
assays relative to the three triple cascade assays (Table 1). 
The IC50 for the triple cascade assays is comparable to the 
~70 nM IC50 observed for U0126 inhibition of MEK1 activa-
tion observed in Swiss 3T3 cells, while the >10 μM potency 
observed for the MEK1 double cascade is consistent with the 
13 μM IC50 reported for U0126 inhibition of MEK1 [27]. 
The suggestion from our data for a compound with unknown 
mode of action is that the potent level of inhibition (~65 nM) 
likely is for RAF activity and/or MEK1 activation, while the 
low inhibitory activity (μM potency) is likely for active 
MEK1. U0126 had very weak inhibitory activity in the B-
RAF, B-RAF V599E, and C-RAF TR-FRET direct assays 
(Table  1). Therefore, the TR-FRET data suggests that the 
potent U0126 inhibitory activity observed in the triple cas-
cade is specific for unactivated MEK1, not for active RAF. 
Furthermore, the fact that U0126 does not strongly inhibit 
the C-RAF TR-FRET direct assay suggests that the fluo-
rescein labeling of MEK1 sterically blocks the MEK1 allos-
teric site that binds U0126.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Inhibitor titrations are shown for the FRET assays: ERK2 
direct (); MEK1-ERK2 double cascade (); B-RAF-MEK1-
ERK2 triple cascade (); B-RAF V599E-MEK1-ERK2 triple cas-
cade (); and C-RAF-MEK1-ERK2 triple cascade (). For all 
assay formats, concentrations of active and unactivated enzymes 
were optimized in order to achieve 10 - 50% phosphorylation of the 
FRET substrate in the presence of 100 μM ATP and the absence of 
inhibitor. Two of the compounds tested are known to inhibit RAF 
activity, GW5074 (A) and ZM336372 (B). The other two com-
pounds are allosteric MEK inhibitors: U0126 (C) can differentially 
inhibit MEK activity as well as MEK activation, while PD98059 
(D) inhibits RAF phosphorylation of MEK but not MEK activity. 
All data points represent the mean ± standard deviation from quad-
ruplicate samples.  
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  PD98059 is an allosteric MEK inhibitor that has been 
reported to inhibit MEK1 activation, but not MEK1 activity 
[25, 27, 28]. Our results showing that the three RAF triple 
cascades have similar IC50 values and that no inhibition was 
observed for the MEK1 double cascade or ERK2 direct as-
says were consistent with this mechanism of action (Fig. 6D, 
Table  1). PD98059 did not inhibit the B-RAF, B-RAF 
V599E, or C-RAF direct assays (Table 1). Again, the TR-
FRET data would confirm that the inhibitory activity ob-
served in the triple cascade was specific for unactivated 
MEK1, not for active RAF.  
  By determining a compound’s inhibitory profile against a 
series of kinases, alternate targets that may be valuable for 
therapeutic intervention or deleterious due to off-target inter-
actions can be revealed. Using the FRET-based assay tech-
nology described, we have developed assays for over 230 
kinases. We used these assays to generate an inhibition pro-
file for the RAF inhibitor BAY-43-9006 (Fig. 7). As ex-
pected, B-RAF, B-RAF V599E, and C-RAF were inhibited 
and the inhibition was more pronounced using 10 μM vs. 1 
μM BAY-43-9006 (91% vs. 50%, 44% vs. 13%, and 93% 
vs. 71% inhibition, respectively). Other kinases reported to 
be inhibited by BAY-43-9006, were also detected using 1μM 
BAY-43-9006: VEGFR2 (48%), VEGFR3 (40%), FLT3 
(89%). Additional kinases on the 231 panel that displayed > 
40% inhibition by 1 μM BAY-43-9006 were: RET (77%), 
RET Y791F (80%), RET V804L (44%), FMS (58%), 
PDGFR  V561D (101%), HIPK1 (45%), and FLT3 D835Y 
(45%). Interestingly, despite complete inhibition of PDGFR 
 V561D using 1 μM BAY-43-9006, increasing the concen-
tration to 10 μM BAY-43-9006 resulted in no inhibition of 
PDGFR  D842V mutant (3%), weak inhibition of PDGFR 
 T674I mutant (37%), and moderate inhibition of PDGFR 
 (75%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Radial plot of the inhibition of 1 μM BAY-43-9006 
against 231 kinases using the FRET-based assays. For each of the 
six areas numbered, kinases represented within each area and the 
percent inhibition observed are listed. Area 1: RET (77%), RET 
V804L (44%), and RET Y791F (80%). Area 2: VEGFR2 (48%), 
VEGFR3 (40%), and FMS (40%). Area 3: FLT3 (89%), FLT3 
D835Y (45%), and PDGFR  (33%). Area 4: PDGFR  V561D 
(101%). Area 5: C-RAF (50%), B-RAF (13%), and B-RAF V599E 
(71%). Area 6: HIPK4 (45%).  
DISCUSSION 
  The RAF/MEK/ERK signaling pathway is ubiquitious in 
eukaryotic cells and regulates numerous physiologic proc-
esses such as cellular proliferation, differentiation, and sur-
vival [29]. The over-activation of RAF due to dysregulated 
signaling upstream of RAF or due to mutations within RAF 
are involved in numerous stages of cancer, including tumor 
formation, angiogenesis, metastasis, and resistance to thera-
peutic regiments [14]. As a result, the RAF pathway has 
been targeted in drug discovery. We developed two assay 
formats (FRET-based and TR-FRET-based) that allow inter-
rogation of steps within the RAF-MEK-ERK signaling 
pathway using a combination of cascade and direct assay 
formats. We have found that the ratiometric method for 
FRET data analysis dramatically reduces well-to-well vari-
ability, which contributes to the excellent Z’ values ( 0.5) 
we observed, even under reaction conditions that produced 
low percent phosphorylation. We show here that a traditional 
plot of the ATP concentration vs. the rate of product forma-
tion can be employed to determine the ATP Km for a kinase 
in the FRET direct format. In addition, we have now suc-
cessfully recapitulated the RAF-MEK-ERK pathway using a 
triple cascade FRET approach.  
  For the FRET and TR-FRET assays, we were able to 
determine IC50 values for several reference compounds. The 
known RAF1 inhibitor, GW5074, had IC50 values for the 
RAF triple cascade assays and RAF direct TR-FRET assays 
of 2 - 9 nM and 5 - 24 nM, respectively (Table 1). These 
values are in agreement with the published GW5074 IC50 
value of 9 nM for C-RAF [23]. A second known RAF1 in-
hibitor, ZM336372, has been shown to have an IC50 of 70 
nM for C-RAF [24]; we obtained similar IC50 values for C-
RAF using the FRET and TR-FRET assays (30 nM and 90 
nM, respectively). ZM336372 is reported to have 10-fold 
selectivity for C-RAF over B-RAF and we observed ~6-13-
fold selectivity using the FRET and TR-FRET assays. 
U0126 has a weak ability to inhibit MEK1 with an IC50 of 13 
μM, but an ~100-fold preferential inhibition of MEK1 acti-
vation determined via radiometric kinase assays [27]. This is 
in agreement with the >10 μM IC50 we observed for the dou-
ble cascade MEK1 FRET-based assay, and the ~65 nM IC50 
observed for the FRET-based RAF triple cascades. PD98059 
inhibits MEK1 activation by RAF, but not MEK1 activity 
[25, 27, 28]. Using ~300 nM MEK1 as a substrate, PD98059 
inhibited the activation of MEK1 by C-RAF with an IC50 of 
2-7 μM [28]. Our FRET-based assay results are consistent 
with the reported mechanism of action for PD98059, but the 
IC50 observed in the FRET triple cascade assays were sub-
stantially lower, ~300-420 nM. The difference may be par-
tially due to the ~15-fold lower concentration of MEK1 (20 
nM) used in the FRET-based triple cascade assays compared 
to the previous report (300 nM MEK1).  
  The successful development of FRET-based assays was 
dependent on the ability to design a peptide substrate for a 
given kinase that also contains a protease cleavage site 
proximal to the phosphorylation site. Since the original re-
port documenting this approach to kinase assays [21], we 
have developed assays for over 230 kinases utilizing a set of 
31 peptide substrates. This set of assays is useful for com-
pound profiling, as was demonstrated using the multi-kinase 
inhibitor BAY-43-9006. Using this approach, we were able 
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to identify kinases that are known to be inhibited by BAY-
43-9006, including C-RAF, B-RAF V599E, VEGFR2, 
VEGFR3, and FLT3. Recently, BAY-43-9006 has shown 
potent inhibition of RET, RET V804L, and RET V804M, 
which are associated with medullary and papillary thyroid 
carcinomas [30]. Our results extend this work, and demon-
strate more potent inhibition of the RET mutant Y791F rela-
tive to RET V804L mutant. BAY-43-9006 has also been 
reported to inhibit the oncogenic fusion protein of FIP1-like 
protein and PDGFR that causes eosinophilic leukemia; the 
T674I mutant of this fusion protein is imatinib-resistant [31]. 
We demonstrate inhibition of the isolated PDGFR T674I 
mutant kinase and show that the PDGFR V561D mutant is 
more sensitive to BAY-43-9006 inhibition, while the 
PDGFR D842V mutant is insensitive to BAY-43-9006. 
Both the PDGFR V561D and PDGFR D842V mutants 
are activating mutations found in gastrointestinal tumors 
[32]. Our profiling results may indicate a use for BAY-43-
9006 in patients bearing PDGFR V561D mutants, but not 
in patients bearing PDGFR D842V mutants.  
  Traditional radiometric RAF/MEK/ERK cascade assays 
have been reported [33], and several reports have been re-
cently published describing fluorescent methods to target the 
RAF signaling pathway [34, 35] or the cancer Osaka thyroid 
(COT) signaling pathway [36, 37]. Mallon and colleagues 
described a cascade utilizing active C-RAF, unactivated 
MEK1, and unactivated ERK2 in which phosphorylated 
ERK2 was detected using a europium labeled antibody in a 
non-homogenous DELFIA format [34]. In this assay, the 
RAF kinase cascade assay was conducted in 96-well plates; 
the stopped reactions were transferred to assay plates to al-
low capture of the GST-ERK2 substrate, and wash-
ing/incubation steps occurred with the phospho-ERK2 anti-
body, and with the europium-labeled secondary antibody. 
These authors employed secondary assays for measuring 
RAF phosphorylation of MEK1 via  western blot, and for 
measuring MEK1 activity via an assay similar to their RAF 
cascade, except RAF was eliminated and active MEK1 was 
used. Although successful for the compound characteriza-
tion, the non-homogenous nature of this assay as well as the 
secondary assays (involving plate transfer and washing) is 
cumbersome and increases potential for error in the drug 
discovery process. Newbatt and colleagues described a non-
homogeneous europium-based DELFIA cascade assay utiliz-
ing active B-RAF V599E, unactivated MEK1, unactivated 
ERK2, and ELK1 as the substrate for ERK2 [35]. The B-
RAF V599E kinase cascade assay was conducted in 384-
well plates in which the ELK1 substrate was coated, washed 
and blocked prior to conducting the kinase reaction. Follow-
ing the kinase reaction, the plates were washed, incubated 
with a combination of primary phospho-ELK1 and euro-
pium-labeled secondary antibodies, and finally washed again 
prior to addition of the enhancement solution. To understand 
the point of action for inhibitors within the cascade assay, 
Newbatt and colleagues employed two non-homogeneous 
secondary assays: (1) an activated MEK1 assay using unac-
tivated ERK2 and ELK1 as a substrate, analogous to the 
RAF cascade; and (2) an activated B-RAF V599E direct 
assay using GST-MEK1, glutathione coated plates, anti-
phosho-MEK antibody, and europium-labeled secondary 
antibody [35]. The work of Newbatt et al. [35] produces 
some improvements over the assays used by Mallon et al. 
[34]; these include miniaturization to 384-well plates and 
elimination of the transfer step. However, the necessity to 
coat the substrate onto the assay plate, wash & block the 
plates prior to the kinase assay, and wash the assay plate 
after addition of antibodies adds significant amounts of labor 
and increased opportunity for error. Jia and colleagues de-
scribed the use of a homogeneous time-resolved fluores-
cence (HTRF) cascade format for COT, C-RAF, and MEK1 
utilizing biotinylated-myelin basic protein (MBP) as the ter-
minal substrate [36]. The assay sequence involved the fol-
lowing: (1) 40 μL kinase reactions in 96-well half-volume 
plates; (2) addition of stop reagent; (3) addition of europium 
labeled anti-phopho-MBP antibody and allophycocyanin-
labeled streptavidin; (4) overnight incubation at 4°C. The 
homogenous time-resolved nature of this assay is an im-
provement over previous work, but struggles from the use of 
an overnight incubation at 4°C and a 96-well plate format.  
  The RAF and MEK1 cascade format FRET-based assays 
that we describe offer significant improvements for reagent 
use, time, and labor. The assays we have developed are con-
ducted as 10 μL kinase reactions in 384-well plates, and re-
quire only two sequential one hour incubations at room tem-
perature. The FRET cascade, as well as the direct, assays 
offer the ability to quantify the level of phosphorylation 
achieved on each assay plate by simple inclusion of three 
controls (a no inhibitor control, a 0% phosphorylation con-
trol, and a synthetic 100% phosphorylation control), thereby 
ensuring that the assay was conducted within the linear range 
of the kinase reaction. The Z’ values obtained for the FRET 
cascade assays were 0.5 at <10% phosphorylation, indicat-
ing that a robust inhibitor screen could be run at low levels 
of phosphorylation. The FRET-based and TR-FRET-based 
secondary assays we employed to interrogate the location of 
inhibitor action were also homogeneous, required two se-
quential one hour room temperature incubations, and re-
sulted in assays with Z’  0.5. Both the FRET-based and TR-
FRET-based kinase assay formats utilized a ratiometric 
method for data analysis that reduced well-to-well variabil-
ity. In addition to these common advantages for the FRET-
based and TR-FRET based assays, there are several advan-
tages that are unique to either format. A specific benefit of 
the TR-FRET assay we employed is the inherent resistance 
to common forms of assay interference such as colored, fluo-
rescent, or precipated compounds [22]. Although these forms 
of interference can be a problem for non-time-resolved fluo-
rescent assays, they can be mitigated for in the FRET-based 
assay by running control reactions with compound and as-
sessing the effect on the fluorescent emissions. A specific 
benefit of the FRET-based approach is the ability to develop 
kinase assays without an antibody. The FRET-based cascade 
assays also offer the potential to develop assays for kinases 
that require binding to the native substrate’s tertiary structure 
and thereby allow the identification of allosteric inhibitors 
for kinases within the cascade.  
  Recently, various COT kinase assay formats were com-
pared for the purpose of identifying an assay suitable for 
finding inhibitors of COT activity [36]. Using three direct 
COT assays that each had a different substrate, the authors 
concluded that use of the unactivated MEK1 protein as a 
substrate can result in the identification of compounds that 
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inhibiting COT. These compounds (similar to PD98059 or 
U0126) were not valuable to these authors since they were 
seeking compounds that specifically interacted with COT. In 
our direct C-RAF TR-FRET assay, we employed a fluo-
rescein-labeled-unactivated-MEK1 to assess inhibitors of C-
RAF activity. Using this assay, neither U0126 nor PD98059 
significantly inhibited C-RAF, while the known RAF inhibi-
tors GW5076 and ZM336372 produced IC50 values consis-
tent with literature values. An explanation for the lack of 
inhibition by U0126 & PD98059 is that one of the fluo-
resceins that label MEK1 sterically blocks the MEK1 allos-
teric site that binds U0126 and PD98059. This is an advan-
tage for researchers interested in identifying compounds that 
specifically inhibit MAP3K by binding to MAP3K rather 
than by binding to MEK. Kinase titrations for other 
MAP3K’s using fluorescein-unactivated-MEK1 as a sub-
strate in the direct TR-FRET assay are shown in Fig. (5B). 
For researchers interested in compounds that act within the 
RAF-MEK-ERK pathway and possibly through allosteric 
binding sites such as those of MEK1 that are bound by PD-
0325901 or ARRY-142886, the cascade approach is desir-
able. Deconvolution of the triple cascade can readily be ob-
tained using high-throughput compatible double cascade and 
direct assays, as demonstrated here.  
CONCLUSION 
  The RAF/MEK/ERK signaling pathway forms a critical 
link between extra-cellular stimuli and intra-cellular re-
sponses that ultimately regulate cellular proliferation, differ-
entiation, mobility, and survival. Mutation of RAF or over-
activation of RAF via aberrant upstream signaling impacts 
numerous stages of tumorigenesis. The series of assays we 
have developed target the RAF/MEK/ERK pathway and 
allow the identification of compounds that act in an orthos-
teric or allosteric manner as well as the deconvolution of the 
inhibitory activity. These fluorescent assays utilize a ho-
mogenous low volume high-throughput format, employ rati-
ometric data analysis leading to decreased well-to-well vari-
ability, can be conducted at low substrate conversion with Z’ 
 0.5, and require only two sequential one hour room tem-
perature incubations. As the benefit to knowing a com-
pound’s inhibitory potential against multiple kinases grows, 
the need to determine the inhibition profile expands. Since 
the FRET-based assay format has been successfully applied 
to over 230 kinases, it is well suited for compound profiling. 
In summary, the identification of RAF/MEK/ERK pathway 
inhibitors hold the potential to have clinical impact and fac-
ile methods should enable further drug discovery in this 
pathway, and the assays that we have described should aid in 
those efforts.  
ABBREVIATIONS 
FRET  =  Förster-resonance energy transfer 
MAPK  =  Mitogen-activated protein kinase 
MAP2K  =  Mitogen-activated protein kinase kinase 
MAP3K  =  Mitogen-activated protein kinase kinase kinase 
RTK  =  Receptor tyrosine kinase 
TR-FRET =  Time-resolved Förster-resonance energy trans-
fer 
ACKNOWLEDGEMENTS 
  We are grateful to Steve Riddle and Kevin Vedvik for the 
initial development of the fluorescein-MEK1 substrate and 
terbium-labeled phospho-[Ser 217/221] MEK1 antibody.  
REFERENCES 
[1]  Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated 
protein kinase: conservation of a three-kinase module from yeast to 
human. Physiol Rev 1999; 79(1): 143-80. 
[2]  Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et 
al. Constitutive activation of the 41-/43-kDa mitogen-activated pro-
tein kinase signaling pathway in human tumors. Oncogene 1999; 
18(3): 813-22. 
[3]  Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. 
Activation of mitogen-activated protein kinase associated with 
prostate cancer progression. Cancer Res 1999; 59(2): 279-84. 
[4]  Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. 
In situ visualization of intratumor growth factor signaling: immu-
nohistochemical localization of activated ERK/MAP kinase in glial 
neoplasms. Am J Pathol 1998; 153(5): 1411-23. 
[5]  Marshall CJ. Specificity of receptor tyrosine kinase signaling: 
transient versus sustained extracellular signal-regulated kinase acti-
vation. Cell 1995; 80(2): 179-85. 
[6]  Bos JL. ras oncogenes in human cancer: a review. Cancer Res 
1989; 49(17): 4682-9. 
[7]  Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. 
Kirsten ras mutations in patients with colorectal cancer: the multi-
center "RASCAL" study. J Natl Cancer Inst 1998; 90(9): 675-84. 
[8]  Garnett MJ, Marais R. Guilty as charged: B-RAF is a human onco-
gene. Cancer Cell 2004; 6(4): 313-9. 
[9]  Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of 
the RAF-ERK signaling pathway by oncogenic mutations of B-
RAF. Cell 2004; 116(6): 855-67. 
[10]  Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene 
in human cancer. Nature 2002; 417(6892): 949-54. 
[11]  Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an on-
cogene in melanocytes. Cancer Res 2004; 64(7): 2338-42. 
[12]  Ikenoue T, Hikiba Y, Kanai F, et al. Different effects of point mu-
tations within the B-Raf glycine-rich loop in colorectal tumors on 
mitogen-activated protein/extracellular signal-regulated kinase 
kinase/extracellular signal-regulated kinase and nuclear factor kap-
paB pathway and cellular transformation. Cancer Res 2004; 64(10): 
3428-35. 
[13]  Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson 
DA. Suppression of BRAF(V599E) in human melanoma abrogates 
transformation. Cancer Res 2003; 63(17): 5198-202. 
[14]  Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in 
cancer: therapeutic potential of targeting the Raf/MEK/ERK signal 
transduction pathway. Semin Oncol 2006; 33(4): 392-406. 
[15]  Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J. Tumor 
dormancy in vivo by prevention of neovascularization. J Exp Med 
1972; 136(2): 261-76. 
[16]  Folkman J, Kalluri R. Cancer without disease. Nature 2004; 
427(6977): 787. 
[17]  Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad 
spectrum oral antitumor activity and targets the RAF/MEK/ERK 
pathway and receptor tyrosine kinases involved in tumor progres-
sion and angiogenesis. Cancer Res 2004; 64(19): 7099-109. 
[18]  Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of 
ARRY-142886 (AZD6244), a potent, highly selective mitogen-
activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007; 
13(5): 1576-83. 
[19]  Wang JY, Wilcoxen KM, Nomoto K, Wu S. Recent advances of 
MEK inhibitors and their clinical progress. Curr Top Med Chem 
2007; 7(14): 1364-78. 
[20]  Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parame-
ter for Use in Evaluation and Validation of High Throughput 
Screening Assays. J Biomol Screen 1999; 4(2): 67-73. 
[21]  Rodems SM, Hamman BD, Lin C, et al. A FRET-based assay 
platform for ultra-high density drug screening of protein kinases 
and phosphatases. Assay Drug Dev Technol 2002; 1(1 Pt 1): 9-19. 
[22]  Riddle SM, Vedvik KL, Hanson GT, Vogel KW. Time-resolved 
fluorescence resonance energy transfer kinase assays using physio-
logical protein substrates: applications of terbium-fluorescein and Fluorescent RAF Pathway Assays  Current Chemical Genomics, 2008, Volume 1    53 
terbium-green fluorescent protein fluorescence resonance energy 
transfer pairs. Anal Biochem 2006; 356(1): 108-16. 
[23]  Lackey K, Cory M, Davis R, et al. The discovery of potent cRaf1 
kinase inhibitors. Bioorg Med Chem Lett 2000; 10(3): 223-6. 
[24]  Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation 
of Raf by a novel Raf inhibitor. Chem Biol 1999; 6(8): 559-68. 
[25]  Ballif BA, Blenis J. Molecular mechanisms mediating mammalian 
mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK 
cell survival signals. Cell Growth Differ 2001; 12(8): 397-408. 
[26]  Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel 
inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 
1998; 273(29): 18623-32. 
[27]  Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mecha-
nism of action of some commonly used protein kinase inhibitors. 
Biochem J 2000; 351(Pt 1): 95-105. 
[28]  Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 
098059 is a specific inhibitor of the activation of mitogen-activated 
protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 
270(46): 27489-94. 
[29]  Kolch W. Meaningful relationships: the regulation of the Ras/Raf/ 
MEK/ERK pathway by protein interactions. Biochem J 2000; 351 
Pt 2: 289-305. 
[30]  Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition 
of oncogenic RET mutants. J Natl Cancer Inst 2006; 98(5): 326-34. 
[31]  Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibi-
tor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-
PDGFRalpha T674I mutant. Blood 2006; 108(4): 1374-6. 
[32]  Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating 
mutations in gastrointestinal stromal tumors. Science 2003; 
299(5607): 708-10. 
[33]  McDonald OB, Chen WJ, Ellis B, et al. A scintillation proximity 
assay for the Raf/MEK/ERK kinase cascade: high-throughput 
screening and identification of selective enzyme inhibitors. Anal 
Biochem 1999; 268(2): 318-29. 
[34]  Mallon R, Feldberg LR, Kim SC, et al. An enzyme-linked immu-
nosorbent assay for the Raf/MEK1/MAPK signaling cascade. Anal 
Biochem 2001; 294(1): 48-54. 
[35]  Newbatt Y, Burns S, Hayward R, et al. Identification of inhibitors 
of the kinase activity of oncogenic V600E BRAF in an enzyme 
cascade high-throughput screen. J Biomol Screen 2006; 11(2): 145-
54. 
[36]  Jia Y, Quinn CM, Clabbers A, et al. Comparative analysis of vari-
ous in vitro COT kinase assay formats and their applications in in-
hibitor identification and characterization. Anal Biochem 2006; 
350(2): 268-76. 
[37]  Han S, Zhou V, Pan S, et al. Identification of coumarin derivatives 
as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem 
Lett 2005; 15(24): 5467-73. 
 
 
 
Received: January 03, 2008  Revised: January 19, 2008  Accepted: January 23, 2008 
 
 